Theranica Raises $35M to Bring Innovative Migraine Device to the USA

OrthoNext Digital Platform for the JuniOrtho Plating System Receives FDA Clearance

“Together, OrthoNext and the JuniOrtho Plating System provide a complete solution for surgeons looking for a plating system to address the specific demands of advanced deformity and trauma reconstruction of the lower extremities in the pediatric population,” said Orthofix President of Global Orthopedics Paul Gonsalves.

SonarMed, New Pediatric Monitor Alerts Clinicians To Potential Airway Obstructions During Ventilation Launched

"The SonarMed airway monitoring device has revolutionized the way we care for our littlest patients. There is no other device in the world that can tell you where the endotracheal tube is located within the airway continuously in real-time, and whether the tube is obstructed or even partially occluded," said Jamie W. Powers, M.D., MBA, neonatologist at Huntington Hospital in Pasadena, California.

Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases, announced the closing of its round B of financing, of $35 Million, led by aMoon, Israel’s largest healthcare VC. All existing investors of the company – Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa – participated in the round.

Nerivio Migra®, the company’s novel remote neuromodulation device for acute treatment of migraine, is currently under review of the FDA. In October 2018 the company completed a pivotal study with the device, the largest-ever clinical study conducted with a migraine device to support FDA clearance, spanning 12 clinical sites in the US and Israel, with almost 300 migraine patients. The study met its primary endpoint with high statistical significance, and demonstrated high efficacy, safety and tolerability.

“The new funds will allow the company to mass-produce the Nerivio Migra®, and – once cleared by the FDA – to deliver the device to millions of migraine patients in the USA,” said Alon Ironi, CEO and co-founder of Theranica. “They will also enable further development, targeting additional clinical syndromes,” added Ironi. “We chose to start with the USA because this is the largest single market for migraine and headache, and because we were highly impressed by the readiness of the American medical community to apply drug-free, non-addictive solutions for headache and other types of pain,” Ironi explained.

“Theranica’s vision and current stage align well with the investment strategy of our late stage fund,” said Todd Sone, partner at aMoon. “Theranica’s innovative migraine device combines excellent clinical efficacy, safety and tolerability, together with advanced digital technologies to maximize the benefit for patients.”

“This new partnership with aMoon, together with the on-going support from our existing investors, gives Theranica the fuel to commercialize the product, bring it to the masses and ultimately improve migraine therapy worldwide, by turning this innovative, non-invasive, drug-free solution into the first line of treatment,” said Dr. Shimon Eckhouse, Theranica’s co-founder and chairman of the board.

The Nerivio Migra is Investigational Device, Currently Limited by US Federal Law to Investigational Use Only in the United States.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles